Study
Resistance_to_MAPK_inhibitor_induces_internal_duplication_in_BRAF
| Study ID | Alternative Stable ID | Type |
|---|---|---|
| EGAS00001001304 | Other |
Study Description
2 BRAFV600E cell lines that have been made resistance to 1. the BRAF inhibitor PLX4720 and 2. the combination therapy of dabrafenib and trametinib seem to have a internal duplication in the kinase domain. We would like to know if this is caused by a translocation.
Study Datasets 1 dataset.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD00001001846 | 2 BRAFV600E cell lines that have been made resistance to 1. the BRAF inhibitor PLX4720 and 2. the combination therapy of dabrafenib and trametinib seem to have a internal duplication in the kinase domain. We would like to know if this is caused by a translocation. | HiSeq X Ten | 4 |
Who archives the data?
There are no publications available